Gastrolearning II modulo/7a lezione
Il colangiocarcinoma: Epidemiologia, Fattori di rischio e patogenesi
Prof. D. Alvaro - Università di Roma La Sapienza
Il colangiocarcinoma: Presentazione Clinica, Diagnosi e Trattamento - Gastrol...Gastrolearning
Gastrolearning II modulo/8a lezione
Il colangiocarcinoma: Presentazione Clinica, Diagnosi e Trattamento
Prof. D. Alvaro - Università di Roma La Sapienza
Il colangiocarcinoma: Presentazione Clinica, Diagnosi e Trattamento - Gastrol...Gastrolearning
Gastrolearning II modulo/8a lezione
Il colangiocarcinoma: Presentazione Clinica, Diagnosi e Trattamento
Prof. D. Alvaro - Università di Roma La Sapienza
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...Gastrolearning
Gastrolearning III lezione
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Prof. C. Cammà (Università di Palermo)
www.gastrolearning.it
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...Dr. Muhammad Bin Zulfiqar
In these presentation we will discuss the merits, demrits and outcomes of various interventional radiology modalities for the treatment of hepatocellular carcinoma
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...Gastrolearning
Gastrolearning III lezione
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Prof. C. Cammà (Università di Palermo)
www.gastrolearning.it
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...Dr. Muhammad Bin Zulfiqar
In these presentation we will discuss the merits, demrits and outcomes of various interventional radiology modalities for the treatment of hepatocellular carcinoma
Cholangiocarcinoma: Pathology, diagnosis and treatment.Marco Castillo
A brief description with many abdominal imaging of the Cholangiocarcinoma.
Includes definition, epidemiology, pathology, classification, clinical presentation, diagnosis, staging and treatment.
Wesley Campbell, MD, of U.S. Navy Medicine, presents "An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case Discussion and Review of the Literature" for AIDS Clinical Rounds at UC San Diego
Assessment of Renal Function and Serum Levels of Alpha Tocopherol in HIV Sero...paperpublications3
Abstract: Increased Oxidative Stress markers in HIV/AIDS Patients may be as a result of free radicals generation and evidence is accumulating that Highly Active Antiretroviral Therapy (HAART) mimics AIDS progression but may be costly due to its Nephrotoxicity. In this research serum levels of Alpha tocopherol ( α- tocopherol), Urea, Creatinine as well as CD4 Counts were measured in 70 HIV Seropositive Patients (40 on HAART and 30 HAART-Naïve) and Thirty (30) apparently healthy individuals as controls in Federal Medical Centre Katsina, Nigeria.CD4 Counts, Serum Levels of Alpha tocopherol, Urea and Creatinine of HIV-HAART and HAART Naïve were 0.72±0.27mg/dl, 16.8±5.6 mmol/l, 237±123 µmol/l and 646±254cell/µl and 0.3±0.1mg/dl, 10.4±2.9 mmol/l, 91±26 µmol/l and 364±17 cell/ µl respectively. There were significantly (p<0.05) increased CD4 counts, serum levels of Alpha tocopherol, Urea and Creatinine in HIV/AIDS Patients on HAART compared to HAART- Naive. This is an indication that HIV/AIDS are predisposed to oxidative stress and that also HAART has debilitating effects on kidneys.
A case report on Rheumatoid Arthritis with sickle cell traitPARUL UNIVERSITY
A female patient aged 6 years, a suspected case of sickle cell trait (SCT) having symptoms of Rheumatoid arthritis (RA),
while evaluating joint complaints in adult sickle cell disease (SCD) patients, a number of sickle cell-based entities come
to mind such as avascular necrosis, osteomyelitis, bone infarcts, and septic arthritis. RA is a chronic systemic
inflammatory disease, many reports highlighted the occurrence of RA in SCD presenting as diagnostic challenges for
cases with chronic inflammatory arthritis, SCT also have appeared to persist in some populations at a perplexingly high
rate given the degree of early mortality of homozygosity of SCD, our case report showed that not only SCD but if a patient
has SCT they can develop RA as complication. Our case report concludes that during the evaluation of a SCT patient who
presents with chronic synovitis, one should strongly consider the possibility of coexistence of RA and SCT.
Abdominal Pain as Initial Presentation of Lung Adenocarcinomaasclepiuspdfs
Isolated celiac lymph node metastasis (ICLNM), in general, is not common with a reported incidence of 5–10% for lung adenocarcinoma. Lung adenocarcinoma rarely metastasizes to the celiac lymph node leading to abdominal pain. It is not typical for ICLNM to be the initial presentation of lung adenocarcinoma as well. In this case, a 56-year-old man presented with a 4-week history of persistent periumbilical dull pain. Workup was remarkable for celiac lymph node mass which turned out to be adenocarcinoma with unknown primary cancer. Whole body position emission tomography scan and biopsy of the mass with immunohistochemistry could identify lung adenocarcinoma as the primary cancer. After a well-informed discussion of options for chemotherapy drugs with the patient, the decision was made to pursue bevacizumab combined with chemotherapeutics. He was charged home with abdominal pain relief and outpatient follow-up after short-course of chemotherapy.
La terapia medica e chirurgica della malattia perianale di Crohn - Gastrolear...Gastrolearning
Gastrolearning II modulo/21a lezione
La terapia medica e chirurgica della malattia perianale di Crohn
Relatore: Prof. Paolo Gionchetti (Università di Bologna)
Epatocarcinoma: nulla di nuovo sotto il sole - Gastrolearning®Gastrolearning
Gastrolearning II modulo/13a lezione
Epatocarcinoma: nulla di nuovo sotto il sole
Relatore: Prof. Massimo Colombo (Milano)
Discussants: Prof. F. Farinati (Padova), Prof.ssa E. Villa (Modena), Prof. A. Grieco (Roma).
Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®Gastrolearning
Gastrolearning II modulo/8a lezione
Il trattamento chirurgico del colangiocarcinoma
Prof. Gian Luca Grazi - Hepato-Biliary-Pancreatic Surgery National Cancer Institute Regina Elena, Roma
Il ruolo dell'ecoendoscopia nella diagnosi delle lesioni solide pancreatiche ...Gastrolearning
Gastrolearning II modulo/4a lezione
Il ruolo dell'ecoendoscopia nella diagnosi delle lesioni solide pancreatiche
Prof. A. Larghi - Università Cattolica Sacro Cuore (Roma).
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
4. Worldwide incidence (cases/100,000) of CCA
Canadian
0.35
USA
1.67
Costa Rica
0.3 Puerto Rico
0.35
Australian
0.43
New Zeland
0.4
Philippines 1.2
Vietnam 0.1
Korea
Gwangiu 8.75
Daegu 7.25
Busan 7.1
Finland 1.05
Denmark
1.27
UK 2.17
Switzerland 0.45
France1.3
Spain 0.5
Italy
3.36
Poland 0.7
Israel
0.3
Thailand
North East 85
North 14.6
Central 14.4
Non rare cancer > 6/100,000
Rare cancer < 6/100,000
Taiwan 4.7
Japan
Osaka 3.4
Hiroshima 3.05
Singapore
1.45
China
Shanghai 7.55
Qidong 7.45
Hong Kong 2.25
Guangzhou 0.97
South 5.7
China
5. Incidence IH-CCA vs EH-CCA
IH-CCA EH-CCA
China
Korea
Philippines
Singapore
Taiwan
Thailand
VietNam
UK-Scotland
Hong Kong
Shanghai
Khon Kaen
Chiang Mai
Bangkok
Songkhla
Gwangiu
Busan
Daegu
1.1& 0.35&
4.1* 0.6*
7.45* 0.2
2&+ 0.25&+
6.15& + 1.4& +
4.55^$ 4.2^$
3.95^$ 3.15^$
4.1^$ 3.15^$
Italy
Denmark
Japan
France
51.45& 0.25&
6.1& 0.3&
1.95& 0.2&
1.05&* 0.15&*
0.1&* 0
Qidong
1.05& 0.4&
1.1* 0.1*
0.88* 1.55*
0.62# 0.65#
0.2^ 1.1^
Hiroshima
Osaka
1.25& 1.8&
1.3& 2.1&
(# = ICD – 01)
(* = ICD – 03)
(^ = ICD – 10)
(& = ICD – 02)
( = ICD-V9)
(+ = ICD-V10)
USA 0.58* 0.88*
($ = ICD-0)
East
IH > EH
West
EH > IH
6. IH-CCA as a percentage of all primitive liver cancers.
Italy
7. • Lack of uniform classification !
(morphology only, morphology + topography)
•Histological heterogeneity,lack specific markers !
• Anatomical origin difficult to establish(advanced diagnosis) !
•Hilar EH-CCA often classified as IH-CCA !
IH- and EH-CCA epidemiology !
Biases and criticisms !
USA SEER-9 registries, Welzel TM et al. (J Natl Cancer Inst 2006)
ICD-01/02: overreporting of IH-CCA by 13%
underreporting of EH-CCA by 15 %
IH-CCA
EH-CCA
Morphology
Morphology+
topography
Cancer registries
IH-CCA = 20-30 %
EH-CCA = 40-50 %
NOS = 20-40%
IH- and EH-CCA epidemiology !
Misclassification of hilar CCA !
8. Temporal trends in IH- and EH-CCA
incidence/mortality in 1980-2000.
Temporal trends in IH-CCA and EH-CCA mortality in
men from 1979 to 1997 (Khan SA. J. Hepatology 2002)
In different countries, in the 1980-2000 decades
incidence/mortality…
↑ for IH-CCA
=↓ for EH-CCA
More recent data on incidence ….
EH-CCA
IH-CCA
9. Germany Italy
EH-CCA
Temporal trends in IH-/EH-CCA incidence in Korea.
IH-CCA
IH-CCA EH-CCA
Von Hahn et el. Scand J Gastro 2011. Alvaro D. et al. Dig Liver Dis. 2010.
Shin HR et al. J Korean Med Sci 2010
Korea
0.5
1.5
2
2.5
3
3.5
4
1
IH-CCA
EH-CCA
x 100,000
1999 2000 2001 2002 2003 2004 2005
10. Germany Italy
EH-CCA
Temporal trends in IH- and EH-CCA incidence
in Italy, Germany, France, England-Wales, USA.
IH-CCA
IH-CCA EH-CCA
Von Hahn et el. Scand J Gastro 2011. Alvaro D. et al. Dig Liver Dis. 2010.
x 1,000,000
IH-CCA
EH-CCA
England-Wales France
Khan SA et al. J. Hepatology In Press
IH-CCA
EH-CCA
Khan SA et al. J. Hepatology In Press
USA
0.1
0.2
0.3
0.4
0,5
0.6
0.7
0,.
0.9
1
1.1
x 100,000
IH-CCA
EH-CCA
Lepage C. et al. J. Hepatology 2011
IH-CCA
EH-CCA
Khan SA et al. J. Hepatology In Press
USA
11. Temporal trends in IH- and EH-CCA incidence in
Denmark.
Denmark
0.2
0.6
0.8
1.0
1.2
0.4
Jepsen P. et al. J Natl Cancer Inst 2007
x 100,000
IH-CCA
EH-CCA
12. CCA epidemiology: key concepts !
Canadian
0.35
USA
1.67
Costa Rica
0.3 Puerto Rico
0.35
Australian
0.43
New Zeland
0.4
Philippines 1.2
Vietnam 0.1
Korea
Gwangiu 8.75
Daegu 7.25
Busan 7.1
Finland 1.05
Denmark
1.27
UK 2.17
Switzerland 0.45
France1.3
Spain 0.5
Italy
3.36
Poland 0.7
Israel
0.3
Thailand
North East 85
North 14.6
Central 14.4
Non rare cancer > 6/100,000
Rare cancer < 6/100,000
Taiwan 4.7
Japan
Osaka 3.4
Hiroshima 3.05
Singapore
1.45
China
Shanghai 7.55
Qidong 7.45
Hong Kong 2.25
Guangzhou 0.97
South 5.7
China
EH-CCA > IH-CCA IH-CCA > EH-CCA
* EH-CCA incidence stable/decreasing… last 2-3 decades !
* IH-CCA incidence increased in ‟80-2000‟, now stable !
(trend similar to HCC ?)
15. CCA > HCC = 8:1 with O. Viverrini
CCA < HCC = 1:8 without O. Viverrini
O. Viverrini, C. Sinensis and CCA:
Meta-analysis of published literature.
Shin HR et al. Cancer Sci 2010
Sripa B. et al.
Curr Opin Gastro. 2008.
More than 35 million people
worldwide infected !
20-30 years recurrent pyogenic cholangitis →IH-> EH-CCA
x100,000
Liver Flukes:
control of foodborn infection,
mass anthelmintic therapy
16. HCV and CCA:
Meta-analysis of published literature.
Shin HR et al. Cancer Sci 2010
HCV and CCA:
8/11 studies only IH-CCA
3/11 studies IH-CCA EH-CCA
O.R.
El-Serag 2009 2.55 1.50 (NS)
(USA, cohort)
Shahib 2007 7.9 2.8 (NS)
(USA, case-control)
Welzel 4.4 1.5 (NS)
(USA, case-control)
HCV definite risk factor only for IH-CCA
More advanced is the liver disease more
significant the association !
18. HBV and CCA:
Meta-analysis of published literature.
Shin HR et al. Cancer Sci 2010
7/10 studies only IH-CCA examined (3/7 NS)
2/3 studies EH-CCA not associated with HBV !
Therefore, HBV probable risk factor only for IH-CCA !
In general, higher HBV prevalence higher the
significance of the association with CCA !
Incidence rate of IH-CCA
HBsAg+ = 0.43/100,000/year
HBsAg- = 0.09/100,000/year
HR = 4.8
Hepatology 2011
19. IBD
enhances the risk of
CCA in PSC pts ?
Boberg KM. 2002: 394 PSC, CCA associated with IBD(p<0.001)
IBD as potential risk factor for CCA
PSC: CCA incides at 30-50 yrs.
Lifetime Risk= 5-15%; 0.3-1.5%/year.
Burak K. 2004: 167 PSC, CCA not associated with IBD
However….
PSC was not controlled for in the analysis of IBD !
Therefore, …unclear if IBD is an independent risk factor for
CCA nor if it confers additional risk in PSC pts.
20. CCA risk factors
IH-CCA EH-CCA
n= 116 n= 102
Positive hepatitis
virus markers 35 (30.2%) 19 (18.6%) p= 0.048
No putative risk factor
in 60% CCA !
21. CCA risk factors: key concepts !
Canadian
0.35
USA
1.67
Costa Rica
0.3 Puerto Rico
0.35
Australian
0.43
New Zeland
0.4
Philippines 1.2
Vietnam 0.1
Korea
Gwangiu 8.75
Daegu 7.25
Busan 7.1
Finland 1.05
Denmark
1.27
UK 2.17
Switzerland 0.45
France1.3
Spain 0.5
Italy
3.36
Poland 0.7
Israel
0.3
Thailand
North East 85
North 14.6
Central 14.4
Non rare cancer > 6/100,000
Rare cancer < 6/100,000
Taiwan 4.7
Japan
Osaka 3.4
Hiroshima 3.05
Singapore
1.45
China
Shanghai 7.55
Qidong 7.45
Hong Kong 2.25
Guangzhou 0.97
South 5.7
China
EH-CCA > IH-CCA
IH-CCA > EH-CCA
*HCV, HBV
(treated)
*PSC
*LiverFlukes
*HBV, HCV
(untreated)
*Hepatolithiasis
* Increased incidence of IH-CCA in „80-2000 decades
linked with the burden of HCV infection !?
* > 60% CCA, no putative risk factor !
23. Chronic inflammation and CCA
Chronic
Inflammation
(flukes,PSC..)
Apoptosis
Proliferation
iNOS
NO
Nitrosylation DNA basis
and DNA repair proteins, caspase 9
Mutagenesis
IL6
TNF
COX-2
PgE2
24. HISTOLOGICAL VARIATION OF CCA(Komuta et al. Hepatology 2012)
EH-CCA IH-CCA
100 % 44 % 28 % 28 %
Mixed-CCAMucin-CCA
25. Mucin-producing CCA
From PBGs or mucin-producing
cells
“mixed” IH-CCA, cholangiolo-CCA,
From HPC or non mucin-producing
cuboidal cells in C. Hering and bile
ductules
CLASSIFICATION OF PRIMITIVE LIVER CANCERs:
based on cells of origin (Alvaro D. Hepatology 2012)
26.
27. CSCs and Liver Cancers
•Cancerogenesis
•Prognosis
•Target of treatment
28. To investigate Cancer Stem Cells
in human CCA and its subtypes,
in primary cultures of human CCA and in
established CCA cell lines.
CSC markers:
CD44 (hyaluronan receptor)
“Mesenchymal”: CD90 (Thy-1)
“Quiescent”: CD13(amino peptidase N)
“Epithelial”: CD133 (prominin-1)
EpCAM (pan-epithelial
differentiation antigen)
LGR5(receptor for Wnt-agonistic
R-spondins)
29. RESULTS
Immunophenotype of Mixed-IHCCA
*Mixed-IHCCAs diffusely positive for K7, EpCAM, CD13 and CD133.
*LGR5 restricted to few tumor epithelial cells (arrows).
* CD90 and αSMA mostly expressed by tumor stromal cells (arrows).
PAS CK7 EpCAM CD133
LGR5 CD13 CD90 αSMA
60%
diffuse staining
Few cells
30. Immunophenotype of Mucin-IHCCA
*Mucin-IHCCAs diffusely positive for K7, EpCAM, LGR5, CD133;
*CD13 restricted to few tumor epithelial cells (arrow);
*CD90 and αSMA mostly expressed by tumor stromal cells(arrows)
No difference between IH- and EH- mucin-CCAs.
LGR5 = Mucin-CCA > Mixed-IHCCA (p<0.05)
CD13 = Mixed-CCA > Mucin-CCA (p<0.05)
PAS CK7 EpCAM CD133
LGR5 CD13 CD90 αSMA
60%
diffuse staining
Few cells
31. IH-MIXED
Primary Cultures of Mucin-CCA and Mixed-CCA
IH-MUCIN IH-MIXED
Total cell population
Cells immunosorted for CSC surface markers
32. CCA CSCs: TUMORIGENIC POTENTIAL.
IN VITRO: Spheroid formation
IN VIVO:
1. Subcutaneous xenographts
2. Intrahepatic xenograpths
-normal liver
-CCL4-cirrhotic liver
36. Subcutaneous tumor xenographts, Mucin- vs Mixed-CCA.
H&E H&EH&E
CD133+ CD13+ CD90+
PCNA αSMAH&E
PAS
K19
Xenographts from CD133+/mucin-CCA Xenographts from CD90+/mixed-CCA
Subcutaneous Xenographts from mucin-CCA Xenographts from mixed-CCA
CD133 CD13 CD90 CD133 CD13 CD90
PAS + + - - - -
K19 + + - + + +
Ductular-like structures NO NO NO YES YES YES
37. In vivo tumorigenicity: intrahepatic tumor xenographts.
Cancers only reproduced by iniecting CSCs in the cirrhotic (CCL4)
but not normal livers and only with cells immunosorted from mucin-CCA.
CD133+
Original
Human Mucin-CCA
Tumor xenographt; CD133+ immunosorted from
mucin-CCA and injected in the cirrhotic liver.
Tumor xenographt; CD90+ immunosorted from mucin-CCA and
injected in the cirrhotic liver.
38. Effect of the PI3-kinase/AKT inhibitors, NVP-BEZ235 and
MK2206 (AKT inhibitor), on cell proliferation in primary
cultures of Mucin- or Mixed-CCAs.
NVP-BEZ235 (PI3-kinase inhibitor) and, to a lower extent MK2206 (AKT
inhibitor) are highly active against Mucin- and Mixed-CCAs.
IH-MIXED
IH-MUCIN
0
20
40
60
80
100
120
0 1 5 10 50 100 1000
Cellviability(%)
NVP-BEZ235 (nM)
NVP-BEZ235: Ic50 = 1.26 ± 0.88 nM
NVP-BEZ235: Ic50 = 1.1 ± 0.14 nM
0
20
40
60
80
100
120
0 0.1 0.5 1 5 10 50
Cellviability(%)
MK2206 (µM)
MK2206: Ic50 = 4.54 ± 2.3 µM
MK2206: Ic50 = 5.6 ± 0.53 µM
39. CSC and cholangiocarcinoma
• CSCs were abundantly represented in human
CCA suggesting …..
CCA as a disease of stem/progenitor cells
40. Therefore, cholangiocarcinoma may be a
disease of stem/progenitor cells, which can be
detected by the increasing expression of albumin
in combination with stem/progeni- tor markers.
N. 34 periphereal IH-CCA associated with O. Viverrini.
Coexpression of albumin and K-19 found in the majority of CCA cells !
Since K19/Albumin coexpression normally found in hepatic progenitor cells before
differentiation into cholangiocytes......CCA develops from the intermediate cell type
according to the maturation arrest theory !
41. Mucin-CCA… a PBG cancer ???
Cardinale V,…. Alvaro D. Hepatology 2011, J. Anatomy 2012, Nature Rev . 2012.
Gland base
(near fibromuscular layer)
Undifferentiated phenotype
(10%)
(EpCAM+ ⁄ - /Lgr5+/CD133+)
Transit-amplifying progenitors
( 25%)
(EpCAM + ⁄ - /PDX1 + ⁄ - ⁄SOX17 +/- ⁄ Lgr5-)
Gland body
(middle of the duct wall)
Neck of PBGs
(close contact with surface
epithelium)
Mature cells
(cholangiocytes, goblet cells, pancreatic cells, hepatocytes)
Intermediate phenotype
(EpCAM+⁄PAS+, EpCAM+ ⁄ SR+,
EpCAM+insulin+, EpCAM+ ⁄ albumin+/K19+)
42. (Cardinale V….Nature Rev. 2012)
Mucin-CCA: typical sites of emergence
correspond to the highest density of PBG !
43. Mucin-producing cholangiocarcinoma might derive from Biliary Tree
Stem/progenitor Cells located in PBGs.
Cardinale V….Carpino G, Gaudio E, D. Alvaro. Hepatology 2012.
Mucin-CCAM
44. Mucin-CCA, Pancreatic cancer and Colorectal cancer.
Similar cancers originating from similar glands ?
Cardinale V,…. Alvaro D. Hepatology 2011, J. Anatomy 2012, Nature Rev . 2012.
Peribiliary Glands
Stem cells: CD133, EpCAM, Lgr5
Mucin-CCA
CSCs: CD133, EpCAM, Lgr5
Pancreatic duct glands
Pancreatic ductal adenoK
CD133, EpCAM, Lgr5
Colon crypts
CD133, EpCAM, Lgr5
CD133, EpCAM, Lgr5
Human ColoRectal Cancer
CD133, EpCAM, Lgr5
45. KRAS mutations are frequent in Mucin-CCAs (Komuta M et
al. Hepatol. 2012)
EH-CCA IH-CCA
28 % 28 %100 % 44 %
Kras mutation reflects the different cholangiocytes pheno- and
genotype in intrahepatic cholangiocarcinoma.
KRAS mutations only in muc-CCAs
(41.4% )
48. Hepatology 2012, 55: 2040-41.
Cystic and Papillary Neoplasm Involving Peribiliary Glands: A
Biliary Counterpart of Branch-Type Intraductal Papillary Mucinous
Cystic Neoplasm?
49. CCA develops through a multi-step process involving
separate precursor pathways.
Similarities between CCA and pancreatic cancer.
Intraductal Papillary Biliary Neoplasm (IPBN) Mucin-CCAPeribiliary Glands
Pancreatic duct glands
Pancreatic duct adenoKIntraductal Papillary Muc. Neoplasm (IPMN)